PIN40 PREVALENCE AND QUALITY OF LIFE OF PATIENTS SUFFERING FROM HERPES LABIALIS WITH IN FRANCE—INSTANT STUDY  by Stalder, JF et al.
760 Abstracts
OBJECTIVE: To estimate the patterns of medical care
and associated direct medical costs of managing chronic
hepatitis B virus (HBV) in France. METHOD: Five stages
were identiﬁed to describe the natural history of the
disease: Chronic hepatitis B without complications, com-
pensated cirrhosis, decompensated cirrhosis, hepatic
transplantation (ﬁrst and second year), and hepatocellu-
lar carcinoma. Standard care and corresponding items of
medical resources for these different states of health were
deﬁned on the basis of a literature review and the con-
clusions of an experts panel. Resources included ofﬁces
visits, procedures, laboratory tests, drugs (including
antiviral drugs), and hospitalizations. For each state, the
annual mean unit direct medical costs were estimated
using the weighted proportion of patients using the
resource. Unit costs (2001 value) were nationally avail-
able from the perspective of the French national insur-
ance. RESULTS: Approximately 24% of HBV patients
are managed with antivirals but these medications
accounted for approximately 45% and laboratory tests
for 30% of treatment costs in the chronic HBV state
(€1093). The mean annual treatment costs for the more
advanced disease states were: compensated cirrhosis
€1134, decompensated cirrhosis €8842 (due primarily to
hospital admissions), hepatic transplantation €84,568
(ﬁrst year) and €9147 (second year), and hepatocellular
carcinoma €9352. CONCLUSIONS: Treatment patterns
for HBV vary across centers in France. The average treat-
ment costs indicate a substantial ﬁnancial burden of HBV
that increases with advanced stages of the disease. Pre-
venting HBV or its advance could result in lowered long-
term treatment expenditures.
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OBJECTIVES: To estimate the prevalence and the quality
of life of subjects suffering from Herpes labialis (HL) in
the French population of adults above 17 years old.
METHODS: A population-based survey was conducted
among 10,000 adults through personal face to face inter-
views by using the quota sampling method (applied on
age, sex, economic working class and woman working
status). The screening was made by asking the subjects if
they have suffered from HL or if they have experienced
a fever blister, within the past 12 months. The quality of
life was assessed with the SF-36 questionnaire among 
the HL subjects identiﬁed and a control group of subjects
not suffering from HL (361 subjects). RESULTS: The
population surveyed was representative of the French
population in terms of age, sex, and geographic living
area. The annual prevalence of HL was estimated: 15.1%,
IC95%[14.1%; 16.1%]. The sex ratio women/men was
2/1 and the mean age was 41 years at the time of the study
versus 47.4 years in the control group (p < 0.01). Among
the HL population 14.2% experienced at least 6 recur-
rences in the past 12 months with a sex ratio women/
men at 3/1. The quality of life was worse in the HL 
population with at least 6 recurrences in the past 12
months than in the control group for both physical 
and mental health. After adjustment on age and sex, SF
36-scores were respectively 47.6 vs. 50.8 for physical
health (p < 0.05) and 45.3 vs. 47.9 for mental health (p
< 0.05). CONCLUSIONS: Herpes Labialis is a common
disease in France with an annual prevalence of 15% in
France. When occurring with at least 6 recurrences in 
the past 12 months, Herpes Labialis has a signiﬁcant
impact on quality of life, as measured by the SF-36 
questionnaire.
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OBJECTIVES: No measure has been available to assess
the impact of recurrent genital herpes (RGH) outbreaks.
Some herpes interventions attempt to abort an outbreak
or reduce its length and/or severity. An instrument was
required to determine the beneﬁt of such interventions
from the patients’ perspective, in the context of a clinical
trial. The objective was to develop a measure of the
impact of outbreaks using items representing functional
limitations of speciﬁc importance to RGH patients.
METHODS: Content was derived via interviews with
RGH patients (n = 40). Face & content validity of the
draft HOIQ were assessed by cognitive de-brieﬁng inter-
views with RGH patients (n = 19). Scaling/psychometric
properties were assessed via a web-survey, whereby par-
ticipants (n = 158) completed the HOIQ on two occa-
sions during an outbreak, with 24 to 72 hours between
administrations. RESULTS: Interviews revealed areas of
functioning affected during an outbreak to include; social,
work and other activities, relationships, personal hygiene,
choice of clothing, need to avoid becoming tired,
worry/anxiety and fear of discovery. De-brieﬁng inter-
views indicated that content was appropriate and the
measure easy to understand and complete. Rasch analy-
sis of survey data yielded a 12-item unidimensional
measure. Assessment of test-retest reliability was not pos-
sible due to rapid change in health status during an out-
break. However, item stability testing indicated that no
items exhibited time-related differential item functioning,
